Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amoxicillin/clavulanic acid controlled release - Avadel Pharmaceuticals

Drug Profile

Amoxicillin/clavulanic acid controlled release - Avadel Pharmaceuticals

Alternative Names: Amoxicillin CR/clavulanic acid IR; Co-amoxyclav XR; Long-acting amoxicillin clavulanate

Latest Information Update: 25 Jan 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Flamel Technologies
  • Class Antibacterials; Beta-lactams; Penicillins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 24 Jan 2017 Discontinued - Phase-I for Infections in France (PO) (Avadel Pharmaceuticals pipeline, January 2017)
  • 23 Oct 2012 Amoxicillin/clavulanic acid controlled release - Flamel Technologies is available for licensing http:www.flamel.com
  • 16 Nov 2010 No development reported - Phase-I for Infections in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top